SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
Following is the text of a press release issued on May 17, 2001:
[LOGO - ICN]
---------------------------------------------------------------------------
ICN PHARMACEUTICALS, INC.
International Headquarters
ICN Plaza
3300 Hyland Avenue
Costa Mesa, California 92626
Telephone: (714) 545-0100 x3230
FAX: (714) 641-7215
Telex: 67-0413
Investors: Media:
---------- ------
Joe Schepers Peter Murphy
212-754-4422 714-545-0100, ext. 3213
ICN PHARMACEUTICALS LAUNCHES ANNUAL MEETING WEB PAGE
COSTA MESA, Calif., May 17, 2001 -- ICN Pharmaceuticals, Inc. (NYSE: ICN),
a research-based global pharmaceutical company, today announced that it has
established a new web page to host information for the Company's 2001
annual shareholders meeting.
The web page contains recent news releases relating to the Company's
current restructuring status, corporate advertisements highlighting the
Company's performance, a comprehensive proxy statement detailing background
information on the Company's current nominees for the Board of Directors.
Two of the current nominees have a pre-recorded video streaming
presentation on the web page. The nominees include: Dr. Ray Irani, Chariman
and CEO of Occidental Petroleum and The Right Honorable Kim Campbell,
former Prime Minister of Canada. There is also a special shareholder
message by Chairman and CEO Milan Panic.
You may view this web page at www.icnpharm.com, www.icnannualmeeting.com
and www.icnproxy.com.
ICN is an innovative, research-based, global pharmaceutical company that
manufactures markets and distributes a broad range of prescription and
non-prescription pharmaceuticals under the ICN brand name. Its therapeutic
focus is on anti-infectives, including anti-virals, dermatology and
oncology. Additional information is also available on the company's website
at http://www.icnpharm.com.
THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995. This press release contains forward-looking statements that
involve risks and uncertainties, including but not limited to, projections
of future sales, operating income, returns on invested assets, regulatory
approval processes, and other risks detailed from time to time in the
Company's Securities and Exchange Commission filings.
####